Europe Ophthalmology Therapeutics Market By Indication (Glaucoma, Dry Eye Syndrome, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Macular Edema And Allergic Conjunctivitis) By End User (Hospitals, Eye Clinics, Diagnostic Centres And Patients), And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018–2023)

Europe Ophthalmology Therapeutics Market By Indication (Glaucoma, Dry Eye Syndrome, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Macular Edema And Allergic Conjunctivitis) By End User (Hospitals, Eye Clinics, Diagnostic Centres And Patients), And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018–2023)

ID: 1108 | Pages: 145 | April 2018 | Region: Europe


Europe Ophthalmology Therapeutics Market was worth $6.44 billion in 2018 and estimated to be growing at a CAGR of 6.9%, to reach $8.98 billion by 2023. The market is showing evident potential in the mentioned forecast period. Ophthalmology deals with the treatment of eye defects and diseases. Age related macular degeneration is the major cause of visual loss in adults in industrialised countries, other conditions associated with vision loss include cataract, diabetic retinopathy, and glaucoma along with low vision.

There are around 25 million people with visual impairment in the Europe. It is estimated that more than 70 million people have eye diseases that are in the early stages which if left untreated may lead to severe impairment.

Europe Ophthalmology Therapeutics is driven by the increasing incidence of vision impairment. Advancements in technology in the field of medicine are also playing a key role in the growth of the market. Growing geriatric population across the continent along with an increase in disposable income of the people are some of the factors adding up to the market growth. However, Stringent regulatory framework and unclear reimbursement policies are also acting as hurdles for market growth. Lack of awareness about various diseases associated with ophthalmology is also a major restraint hindering the market growth.

Europe Market for Ophthalmology Therapeutics is broadly segmented into Indication and End User. On the basis of indication, the market is analysed as Glaucoma, Dry Eye Syndrome, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Macular Edema and Allergic Conjunctivitis. Glaucoma is the largest indication segment accounting for a share of approximately 31% followed by AMD with a share of XX%. Based on End User the market is segmented into Hospitals, Eye Clinics, Diagnostic Centres and Patients. Geographically, Europe Ophthalmology Therapeutics market is segmented into United Kingdom, Germany, France, Italy and Spain. Within Europe, Germany is the largest market for Ophthalmology Therapeutics

Some of the major companies covered in the report are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath and Eye Gate Pharmaceuticals

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Indication                              

                                5.1.1 Glaucoma

                                5.1.2 Dry Eye Syndrome

                                5.1.3 Diabetic Retinopathy         

                                5.1.4 Retinal Vein Occlusion        

                                5.1.5 Age-Related Macular Degeneration (AMD)

                                5.1.6 Macular Edema    

                                5.1.7 Allergic Conjunctivitis         

                5.2 By End User               

                                5.2.1 Hospitals  

                                5.2.2 Eye Clinics

                                5.2.3 Diagnostic Centers              

                                5.2.4 Patients   

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Allergan, Inc.                              

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck & Co Inc                         

                9.3 Pfizer                            

                9.4 Roche                           

                9.5 Novartis (Alcon)                       

                9.6 Valeant                        

                9.7 Regeneron                 

                9.8 Santen                         

                9.9 Bayer                            

                9.10 Senju                          

                9.11 Lpath                          

                9.12 Eye Gate Pharmaceuticals                 

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Europe Ophthalmology Therapeutics Market By Region, From 2018-2023 (USD Bllion)
  2. Europe Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  3. Europe Glaucoma Market By Region, From 2018-2023 (USD Bllion)
  4. Europe Dry Eye Syndrome Market By Region, From 2018-2023 (USD Bllion)
  5. Europe Diabetic Retinopathy Market By Region, From 2018-2023 (USD Bllion)
  6. Europe Retinal Vein Occlusion Market By Region, From 2018-2023 (USD Bllion)
  7. Europe Age-Related Macular Degeneration (AMD) Market By Region, From 2018-2023 (USD Bllion)
  8. Europe Macular Edema Market By Region, From 2018-2023 (USD Bllion)
  9. Europe Allergic Conjunctivitis Market By Region, From 2018-2023 (USD Bllion)
  10. Europe Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
  11. Europe Hospitals Market By Region, From 2018-2023 (USD Bllion)
  12. Europe Eye Clinics Market By Region, From 2018-2023 (USD Bllion)
  13. Europe Diagnostic Centers Market By Region, From 2018-2023 (USD Bllion)
  14. Europe Patients Market By Region, From 2018-2023 (USD Bllion)
  15. U.K Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  16. U.K Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
  17. Spain Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  18. Spain Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
  19. Germany Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  20. Germany Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
  21. Italy Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  22. Italy Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
  23. France Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  24. France Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
Middle-East & Africa Cardiovascular Therapeutic Drugs By Disease (Arteriosclerosis, Cardiac Arrhythmias, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Artery Disease, Coronary Artery Disease, Hypertensi...
Middle East And Africa Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail...
Latin America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Asia Pacific Clostridium Botulinum Market By Product (botulinum Toxin Type A And Botulinum Toxin Type B), By End User (aesthetic And Therapeutics), By Distribution Channel (hospitals, Clinics And Retail Pharmacies) ...
Europe Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And...
North America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And By Reg...
The Dental Bone Graft Substitutes Market Is Predicted To Reach USD 664.3 Million With A CAGR Of 9.8% According To Market Data Forecast Report....
Middle East And Africa Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal D...
Latin America Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Reg...
Asia-Pacific Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Rege...
Europe Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Regenerati...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.